Castle Creek Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Castle Creek Biosciences sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Castle Creek Biosciences: 11 sponsored US clinical trials, none currently recruiting.

Castle Creek Biosciences sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bilateral Nasolabial Fold Wrinkles, with 1 trials.

Top-decile sponsor footprint

Castle Creek Biosciences ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

11 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639
ACTIVE NOT RECRUITING Phase 3

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261
TERMINATED Phase 1

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

NCT03740724
TERMINATED Phase 1

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT02810951
COMPLETED Phase 2

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

NCT02120781
TERMINATED Phase 2

Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

NCT01858753
COMPLETED Phase 2

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

NCT00642642
COMPLETED Phase 2

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases

NCT00654654
COMPLETED Phase 3

Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

NCT00655356
COMPLETED Phase 3

Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

NCT00649428
COMPLETED Phase 2

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

NCT00655889

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 4

Therapeutic Areas

Bilateral Nasolabial Fold Wrinkles 1
Recessive Dystrophic Epidermolysis Bullosa 1
Dystrophic Epidermolysis Bullosa 1

How the Castle Creek Biosciences early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 6 completed (55%).

Phase mix: 4 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Bilateral Nasolabial Fold Wrinkles (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Castle Creek Biosciences: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Castle Creek Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Castle Creek BiosciencesAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Castle Creek Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Castle Creek Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Castle Creek Biosciences page

11 registered trials is a research-attention snapshot, not an endorsement of Castle Creek Biosciences or any single study.

  • None of Castle Creek Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bilateral Nasolabial Fold Wrinkles is the condition Castle Creek Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bilateral Nasolabial Fold Wrinkles trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Castle Creek Biosciences pipeline card: 11 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.